
彰化基督教醫學中心薪資資料曝光,麻醉科平均月薪60.9萬元,胸腔外科最高達157.7萬元
彰化基督教醫學中心薪資資料曝光,胸腔外科醫師平均月薪達157.7萬元,刷新業界天花板;心臟外科143.9萬元,麻醉科60.9萬元,皮膚科32.4萬元。總院長陳穆寬指出,採購議價公開透明、省下營運成本回饋員工,是支撐高薪與低自費醫療的關鍵。
AI-generated summary
新竹馬偕紀念醫院近期招募麻醉科主治醫師,外傳保證月薪達60萬元引發醫界熱議,彰化基督教醫學中心隨即曝光內部薪資資料,顯示胸腔外科平均月薪高達157.7萬元,遠超業界預期。
〔記者湯世名/彰化報導〕新竹馬偕紀念醫院最近招募麻醉科主治醫師,外傳保障月薪達60萬元引發醫界熱議。然而在彰化基督教醫學中心,這個數字竟還算「中間區帶」!彰基薪資資料曝光,麻醉科醫師平均月薪達60.9萬元,而全院奪冠的「胸腔外科」平均月薪竟高達157.7萬元,一舉刷新業界天花板,羨煞不少同業。
彰基除了胸腔外科睥睨群雄,心臟外科醫師每月平均也有143.9萬元,耳鼻喉暨頭頸外科則為64萬元;相對而言,皮膚科月薪約32.4萬元落在低薪區。彰基強調,院內採「不同工不同酬」,越辛勞、風險越高的科別,薪水就給得越高。
許多網友好奇,彰基自費醫療比例偏低,究竟如何支撐如此優渥的待遇?彰基總院長陳穆寬親自揭密,該院自費項目堪稱全台醫學中心最低,能給出頂級薪資,關鍵在於「採購議價公開透明」,總院長不介入議價,將省下的營運成本直接回饋給員工。
「醫療是價值,不是價格!」陳穆寬指出,彰基秉持「行公義好憐憫」精神,讓窮人看得到病、富人也搶著來。員工福利越好,就越能用心照顧病人。這些看似「都市傳說」的高薪與低自費,正是彰基照顧員工與患者的日常。
彰基總院長陳穆寬堅持採購議價公開透明、把福利給員工。(資料照)
AI outlook — possibilities, not facts
其他台灣醫學中心可能效仿彰基的採購透明化與成本回饋模式,調整醫師薪資結構。
Possible · Within months

A Hong Kong paediatric expert urges parents to vaccinate children against influenza ahead of cooler weather, warning of overlapping summer and winter flu waves after 29 severe paediatric cases and two deaths this season.

The Affiliated Hospital of National Yang-Ming Chiao Tung University celebrated its 130th anniversary and held the 16th International Medical Symposium in conjunction with National University of Yilan on the 7th, focusing on topics such as sustainable medical care, prevention and treatment of childhood myopia, cardiovascular care, and generative AI. Dean Huang Zhixian and President Lin Qihong delivered speeches respectively, and demonstrated the local results of Yilan's reduction of myopia rate among young children from 15.4% to about 8%.

The Taichung Veterans Affairs Center broke ground on the construction of a medical science and technology building at a cost of 4.082 billion yuan. Executive Director Zhuo Rongtai attended and said that our country's health insurance has been recognized internationally, and the government's medical and health insurance budget has increased year by year, exceeding one trillion yuan. The building is expected to be completed in November 2029 and opened in April 2030. It will have core facilities such as an international conference center and an artificial intelligence research center.

There is one new imported case of dengue fever in Tainan. The case is a Chinese female in her 40s from Yongkang District. She developed symptoms 4 days after returning from a trip to Vietnam as an employee and was diagnosed at Annan Hospital. She is the 17th imported case in Tainan this year. The disease management unit has launched emergency spray prevention and control, environmental breeding source removal and vector mosquito density surveys for his residence. As of November 6, there have been a total of 238 cases in the country, including 221 imported cases. Vietnam has the largest number of infected countries.

A research team from Brigham Young University in the United States used nanogene engineering to modify macrophages and reduced solid tumors by 46% in mouse experiments. In in vitro tests, 90% of lung cancer cells were eliminated within 24 hours. The technology has been patented and licensed to biotechnology companies, but it is still in the pre-clinical development stage and has not yet been subjected to human clinical trials, and the relevant results have not been published in peer-reviewed journals.

The FDA is investigating a risk of neoplasia, including malignancy, associated with Novartis' gene therapy Zolgensma. The Swiss drugmaker disclosed two cases of tumors in children linked to the therapy and reported nine tumor cases overall among patients treated since its 2019 approval.